Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
EOLS vs INMD
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
EOLS vs INMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Devices |
| Market Cap | $421M | $882M |
| Revenue (TTM) | $301M | $375M |
| Net Income (TTM) | $-43M | $87M |
| Gross Margin | 65.7% | 77.8% |
| Operating Margin | -9.6% | 21.3% |
| Forward P/E | — | 9.6x |
| Total Debt | $155M | $13M |
| Cash & Equiv. | $54M | $303M |
EOLS vs INMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 100 | 139.8 | +39.8% |
| InMode Ltd. (INMD) | 100 | 95.0 | -5.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EOLS vs INMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EOLS is the clearest fit if your priority is growth exposure.
- Rev growth 11.6%, EPS growth 1.2%, 3Y rev CAGR 26.0%
- 11.6% revenue growth vs INMD's -6.2%
INMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.04
- 105.0% 10Y total return vs EOLS's -44.4%
- Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.6% revenue growth vs INMD's -6.2% | |
| Quality / Margins | 23.3% margin vs EOLS's -14.4% | |
| Stability / Safety | Beta 1.04 vs EOLS's 1.27 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -2.1% vs EOLS's -45.7% | |
| Efficiency (ROA) | 11.8% ROA vs EOLS's -19.4%, ROIC 13.5% vs -44.5% |
EOLS vs INMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EOLS vs INMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
INMD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INMD and EOLS operate at a comparable scale, with $375M and $301M in trailing revenue. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to EOLS's -14.4%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $301M | $375M |
| EBITDAEarnings before interest/tax | -$21M | $81M |
| Net IncomeAfter-tax profit | -$43M | $87M |
| Free Cash FlowCash after capex | -$41M | $91M |
| Gross MarginGross profit ÷ Revenue | +65.7% | +77.8% |
| Operating MarginEBIT ÷ Revenue | -9.6% | +21.3% |
| Net MarginNet income ÷ Revenue | -14.4% | +23.3% |
| FCF MarginFCF ÷ Revenue | -13.7% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.2% | +5.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +46.7% | -30.8% |
Valuation Metrics
EOLS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $421M | $882M |
| Enterprise ValueMkt cap + debt − cash | $522M | $593M |
| Trailing P/EPrice ÷ TTM EPS | -7.99x | 9.73x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.64x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.98x |
| EV / EBITDAEnterprise value multiple | — | 6.88x |
| Price / SalesMarket cap ÷ Revenue | 1.42x | 2.38x |
| Price / BookPrice ÷ Book value/share | — | 1.33x |
| Price / FCFMarket cap ÷ FCF | — | 10.46x |
Profitability & Efficiency
INMD leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +13.3% |
| ROA (TTM)Return on assets | -19.4% | +11.8% |
| ROICReturn on invested capital | -44.5% | +13.5% |
| ROCEReturn on capital employed | -23.5% | +12.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | $101M | -$289M |
| Cash & Equiv.Liquid assets | $54M | $303M |
| Total DebtShort + long-term debt | $155M | $13M |
| Interest CoverageEBIT ÷ Interest expense | -1.92x | — |
Total Returns (Dividends Reinvested)
EOLS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EOLS five years ago would be worth $6,991 today (with dividends reinvested), compared to $3,613 for INMD. Over the past 12 months, INMD leads with a -2.1% total return vs EOLS's -45.7%. The 3-year compound annual growth rate (CAGR) favors EOLS at -10.6% vs INMD's -26.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -4.9% | -5.9% |
| 1-Year ReturnPast 12 months | -45.7% | -2.1% |
| 3-Year ReturnCumulative with dividends | -28.4% | -60.2% |
| 5-Year ReturnCumulative with dividends | -30.1% | -63.9% |
| 10-Year ReturnCumulative with dividends | -44.4% | +105.0% |
| CAGR (3Y)Annualised 3-year return | -10.6% | -26.4% |
Risk & Volatility
INMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INMD is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than EOLS's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INMD currently trades 83.2% from its 52-week high vs EOLS's 52.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.04x |
| 52-Week HighHighest price in past year | $12.16 | $16.74 |
| 52-Week LowLowest price in past year | $3.86 | $12.72 |
| % of 52W HighCurrent price vs 52-week peak | +52.5% | +83.2% |
| RSI (14)Momentum oscillator 0–100 | 76.1 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 804K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EOLS as "Buy" and INMD as "Buy". Consensus price targets imply 134.7% upside for EOLS (target: $15) vs 14.9% for INMD (target: $16).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $16.00 |
| # AnalystsCovering analysts | 13 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.5% |
INMD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EOLS leads in 2 (Valuation Metrics, Total Returns).
EOLS vs INMD: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is EOLS or INMD a better buy right now?
For growth investors, Evolus, Inc.
(EOLS) is the stronger pick with 11. 6% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EOLS or INMD?
Over the past 5 years, Evolus, Inc.
(EOLS) delivered a total return of -30. 1%, compared to -63. 9% for InMode Ltd. (INMD). Over 10 years, the gap is even starker: INMD returned +105. 0% versus EOLS's -44. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EOLS or INMD?
By beta (market sensitivity over 5 years), InMode Ltd.
(INMD) is the lower-risk stock at 1. 04β versus Evolus, Inc. 's 1. 27β — meaning EOLS is approximately 22% more volatile than INMD relative to the S&P 500.
04Which is growing faster — EOLS or INMD?
By revenue growth (latest reported year), Evolus, Inc.
(EOLS) is pulling ahead at 11. 6% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: Evolus, Inc. grew EPS 1. 2% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, EOLS leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EOLS or INMD?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -17. 4% for Evolus, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -12. 7% for EOLS. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EOLS or INMD more undervalued right now?
Analyst consensus price targets imply the most upside for EOLS: 134.
7% to $15. 00.
07Which pays a better dividend — EOLS or INMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is EOLS or INMD better for a retirement portfolio?
For long-horizon retirement investors, InMode Ltd.
(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +105. 0% 10Y return). Both have compounded well over 10 years (INMD: +105. 0%, EOLS: -44. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EOLS and INMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EOLS is a small-cap quality compounder stock; INMD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.